Cellect Biotechnology Ltd. shares rocketed 79% in premarket trade Thursday, after the Israeli company said it has made a breakthrough in a stem cell trial. The company said it has successfully completed transplantation of stem cells in the first group of three patients using its ApoGraft technology in a mid-stage trial. After a month, all three patients had demonstrated full acceptance of the transplant with no adverse events or reactions. The company is planning to recruit another three patients once the data has been reviewed. “The company believes that these interim results of ApoGraft present the first signs of a breakthrough in stem cell transplantation,” it said in a statement. “The product is transplantable within less than 12 hours from donation through a simple process performed on the bedside after selective physiological elimination of immune reaction-causing cells.” Shares have gained 117% in the last 12 months, while the S&P 500 has gained 19%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News